Flag of the European Union EU Clinical Trials Register Help

Clinical trials for First responders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    668 result(s) found for: First responders. Displaying page 1 of 34.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-004748-23 Sponsor Protocol Number: 2011080362 Start Date*: 2011-12-05
    Sponsor Name:Neurologisk Afdeling
    Full Title: Risk of apoplexia cerebri in clopidogrel non-responders.
    Medical condition: Apoplexia cerebri
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004416-78 Sponsor Protocol Number: MRZ 60201-0520/1 Start Date*: 2006-08-30
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, multicenter trial with an open-label extension period to investigate the efficacy and safety of NT 201, free of complexing proteins, in ...
    Medical condition: Treatment of glabellar frown lines
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006495-16 Sponsor Protocol Number: PrEPSo Start Date*: 2022-02-25
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders
    Medical condition: Covid 19 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084458 COVID-19 prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001521-27 Sponsor Protocol Number: SP-1011-003 Start Date*: 2020-08-03
    Sponsor Name:Adare Pharmaceuticals US, LP
    Full Title: Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects w...
    Medical condition: Eosinophilic Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002720-91 Sponsor Protocol Number: HBnr02 Start Date*: 2017-09-21
    Sponsor Name:CyTuVax BV
    Full Title: Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders.
    Medical condition: In a minority of the population (5-10%) standard vaccines against Hepatitis-B do not induce protective immunity, even after prolonged and repeated vaccination courses. Non- responsiveness to hepati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000985-36 Sponsor Protocol Number: EMCAM-2011-001 Start Date*: 2013-02-22
    Sponsor Name:JOSE MANUEL GARCIA DOMINGUEZ
    Full Title: Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as "responders" and "not responders" under t...
    Medical condition: Spasticity due to multiple sclerosis identified as "responders" and "not responders" under treatment with Sativex
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002510-40 Sponsor Protocol Number: DEALSZ-2020-001 Start Date*: 2020-12-28
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety...
    Medical condition: Chronic spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003983-30 Sponsor Protocol Number: CPH-303-201400 Start Date*: 2019-05-22
    Sponsor Name:Croma-Pharma GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study.
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003775-30 Sponsor Protocol Number: CICL670ABE04 Start Date*: 2016-01-18
    Sponsor Name:Novartis Pharma NV
    Full Title: A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in...
    Medical condition: The study will include two groups of patients with low and intermediate 1 risk myelodysplastic syndrome. One group consists of patients who experience an hematological response while on deferasirox...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002263-26 Sponsor Protocol Number: P180101 Start Date*: 2019-05-13
    Sponsor Name:DRCI APHP
    Full Title: Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder
    Medical condition: Adult individuals with bipolar I disorders who initiate lithium treatment based on the decision of themselves and their clinician
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) SE (Completed) DE (Prematurely Ended) DK (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003237-33 Sponsor Protocol Number: HO112 Start Date*: 2013-11-21
    Sponsor Name:HOVON Foundation
    Full Title: Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III t...
    Medical condition: Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    18.0 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002676-27 Sponsor Protocol Number: MedOPP096-MO39229 Start Date*: 2017-05-25
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study
    Medical condition: HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002521-27 Sponsor Protocol Number: 8477-CL-0020 Start Date*: 2014-05-08
    Sponsor Name:Astellas Pharma Europe B.V. (APEB)
    Full Title: A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain
    Medical condition: Peripheral Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    17.1 10029205 - Nervous system disorders 10012683 Diabetic peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004092-40 Sponsor Protocol Number: CAMN107I2201 Start Date*: 2013-03-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disea...
    Medical condition: Adult patients treated with a planned dose of nilotinib 300 mg BID (or at a reduced dose level of 400 mg QD if required from the perspective of tolerance) for a minimum of 2 calendar years for newl...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) IT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IE (Completed) PL (Completed) DK (Completed) NL (Ongoing) GR (Completed) HU (Completed) FR (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011115-20 Sponsor Protocol Number: NordLOTS protocol step 3 1.1 Start Date*: 2009-08-14
    Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)
    Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049596 Obsession LLT
    9.1 10010219 Compulsions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000574-69 Sponsor Protocol Number: D9612L00076 Start Date*: 2006-04-07
    Sponsor Name:AstraZeneca A/S
    Full Title: Development of an algorithm for identification of responders to short term treatment with esomeprazol (Nexium) in primary care.
    Medical condition: acid related disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-001143-59 Sponsor Protocol Number: IVFAFC1 Start Date*: 2006-07-14
    Sponsor Name:School of Human Development
    Full Title: A prospective, randomised study comparing two fixed daily doses (150 IU versus 225 IU) of recombinant FSH for ovarian stimulation during in-vitro fertilisation treatment in predicted low and interm...
    Medical condition: Infertility needing In-Vitro fertilisation treatment
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004531-22 Sponsor Protocol Number: MBA 1/2005 Start Date*: 2006-05-02
    Sponsor Name:Májbetegekért Alapítvány
    Full Title: Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 weeks of Combined Treatment of Patients Receiving Pegasys and Copegus who are Biochemical Responders but Virolo...
    Medical condition: Chronic hepatitis C virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005086-12 Sponsor Protocol Number: GAM-27 Start Date*: 2013-07-05
    Sponsor Name:Octapharma AG
    Full Title: Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis.
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002164-16 Sponsor Protocol Number: CPH-301-201030 Start Date*: 2016-04-11
    Sponsor Name:CROMA-PHARMA GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 12:15:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA